Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion

This publication has 41 references indexed in Scilit:

• Subchronic Antidepressant Treatment with Venlafaxine or Imipramine and Effects on Blood Pressure and Heart Rate: Assessment by Automatic 24-Hour Monitoring
  Pharmacopsychiatry, 1996
• The serotonergic antidepressant nefazodone inhibits the serotonin transporter: In vivo and ex vivo studies
  Life Sciences, 1995
• Pharmacologic profile and efficacy of venlafaxine
  International Clinical Psychopharmacology, 1995
• Should rational drug development in psychiatry target more than one mechanism of action in a single molecule?
  International Review of Psychiatry, 1995
• Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo
  Life Sciences, 1994
• Pharmacology of Antidepressants—Characteristics of the Ideal Drug
  Mayo Clinic Proceedings, 1994
• Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
  Life Sciences, 1993
• Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite
  The Journal of Clinical Pharmacology, 1992
• Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine-treated mice
  General Pharmacology: The Vascular System, 1991
• (—)-m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone
  Journal of Pharmacy and Pharmacology, 1981